Overview
Orexin A (also known as Hypocretin-1) is a naturally occurring neuropeptide produced primarily in the hypothalamus region of the brain, first identified in the late 1990s. It is classified as an orexinergic peptide and plays a recognized role in regulating arousal, wakefulness, and energy balance in vertebrate physiology. Research has also explored its presence and signaling activity beyond the hypothalamus, including in areas such as the retina, suggesting a broader functional distribution across the nervous system. Scientists have studied its relationship to stress responses, trauma, and conditions such as narcolepsy type 1, where low cerebrospinal fluid levels of this peptide have been observed as a biological marker. Orexin A is available for laboratory research purposes only and is not intended for human use or consumption.
Research & Bioactivity
Orexin A (also referred to as hypocretin-1) is a neuropeptide that researchers have studied extensively in relation to the regulation of arousal, sleep-wake cycles, and energy homeostasis. Studies have examined its role as a cerebrospinal fluid biomarker, with research investigating how reduced orexin A levels in CSF correlate with narcolepsy type 1, a finding that has driven significant methodological work comparing radioimmunoassay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification approaches. Research has also investigated the relationship between orexin A signaling and physiological stress responses, with systematic reviews evaluating how trauma and stress-related conditions influence orexin expression across animal and human studies. Beyond its hypothalamic origins, researchers have studied the broader expression of the orexin system in peripheral neural tissues, including the vertebrate retina, where studies have examined its presence across multiple retinal cell types and its potential neuromodulatory role in visual physiology. Collectively, published research has positioned orexin A as a subject of interest across neuroscience, sleep research, and stress biology, with ongoing work focused on refining detection methodologies and understanding its signaling pathways in both central and peripheral tissues.
Published Research
The orexinergic system in the retina: Expression and physiological impact-A review of the literature.
Haddad M — 2026
The neuropeptides orexin-A (OXA) and orexin-B (OXB), central orchestrators of arousal and energy homeostasis, are increasingly recognized as key neuromodulators within the vertebrate retina. This review synthesizes current evidence demonstrating a broad extra-hypothalamic expression of the orexin system across retinal neurons, including photoreceptors, bipolar (BCs), amacrine (ACs), and ganglion cells (GCs). We detail a sophisticated, cell-type-specific signaling framework where orexins exert complex, often antagonistic, presynaptic and postsynaptic actions via orexin 1 (OX1R) and orexin 2 (OX2R) receptors. These actions fine-tune signal transmission by potentiating glutamate release from BCs while suppressing GABAergic inhibition from ACs, ultimately modulating retinal output. A central theme emerging is the system's pivotal role in non-image-forming visual functions: OXA enhances the pupillary light reflex (PLR) by increasing the excitability of specific intrinsically photosensitive retinal ganglion cells (M2 ipRGCs), while OXB potentiates scotopic (dim-light) sensitivity by disinhibiting rod bipolar circuits. Furthermore, pharmacological inhibition of orexin receptors affects circadian rhythms in both the retina and hypothalamus. However, the field is marked by intriguing paradoxes, such as the stimulatory effects of receptor antagonists and significant species differences in OX2R expression. We critically evaluate evidence for a tonically active retinal orexin system that interfaces with dopaminergic signaling and circadian photic input. By integrating molecular, cellular, and behavioral findings, this review clarifies how retinal orexinergic modulation serves as a potential crucial interface between light detection, circadian physiology, and systemic arousal, while highlighting critical translational gaps and future research directions.
Hypocretin-1/ Orexin-A fragment1-16 as a potential surrogate marker for diagnosing narcolepsy type 1.
Wenz ES, Prost JC, Lagache SB, Mäder GM, Warncke JD, et al. — 2026
STUDY OBJECTIVES: Loss of cerebrospinal fluid hypocretin-1/orexin-A (Hcrt-1) immunoreactivity is a biomarker for narcolepsy type 1 (NT1). The current radioimmunoassay (RIA) does not allow precise quantification, limiting the assessment of disease severity and evolution. This study aimed to reproduce previously proposed workflows to quantify Hcrt-1 and Hcrt-2 by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), identify RIA antibody targets, and to compare two purification methods in their ability to identify patients with NT1. METHODS: Solid phase extraction (SPE) and LC-MS/MS measurements of Hcrt-1 and -2 levels from 10 NT1 patients and 21 controls were implemented based on existing literature. Immunoprecipitation (IP) with magnetic beads coupled to the RIA antibody (Phoenix) was performed and peptides identified by MS. Finally, Hcrt-1 (full-length) and Hcrt-1 fragment1-16 levels were analyzed in 4 patients and 4 controls prepared from both workflows by nano-LC coupled to high-resolution mass spectrometry (nLC-HRMS). RESULTS: Despite linear calibration curves for Hcrt-1 and Hcrt-2 (R2 > 0.99) could be assessed with LC-MS/MS, full-length Hcrt-1 concentrations were at the low end of the calibration curve with slightly lower levels in NT1 (p = 0.04). Hcrt-2 was undetectable. The discovery experiment with IP most reliably identified Hcrt-1 fragment1-16. SPE revealed much higher concentrations than IP. Hcrt-11-16-levels allowed distinguishing patients and controls after SPE and IP, whereas full-length Hcrt-1-levels after IP did not. CONCLUSIONS: Hcrt-11-16 appears stable and abundant in CSF of controls, allows identification of patients with NT1 and is a promising surrogate marker. SPE seems more suitable for further method validation in clinical routine.
The impacts of trauma and stress on orexin expression and signalling: A systematic review.
Xiao K, Sayed H, Xing J, Zhang XY, Ai J, et al. — 2026
BACKGROUND: Orexins are excitatory hypothalamic neuropeptides which modulate various stress-related physiological functions. This systematic review aims to evaluate the current literature on the impacts of trauma and stress on orexin expression and signalling. METHODS: A systematic review of primary research was conducted using Embase, PsycInfo, MEDLINE, and PubMed databases from inception to December 2025, following PRISMA criteria. Our search strings included keywords related to trauma, stress, posttraumatic stress disorder (PTSD), and orexins. Both preclinical and clinical studies evaluating the impacts of trauma and stress on orexin expression and signalling were included. RESULTS: In preclinical studies (n = 6), acute stress is associated with increased orexin neuronal activation and concentration (1.55-fold increase, p< 0.05), as well as increased orexin receptor expression in the posterior hypothalamus (1.3-fold increase, p<0.01). Chronic stress and PTSD is associated with increased orexin receptor responsivity (t = 3.51, p= 0.011). Childhood trauma is associated with decreased orexin receptor 1 (OX₁ receptor) expression in the hypothalamus (p< 0.05) and amygdala (2-fold decrease, p<0.05). In a clinical study, childhood trauma was associated with increased plasma orexin-B concentration and Major Depressive Disorder (p < 0.001). CONCLUSIONS: Acute trauma exposure and stress are associated with increased orexin expression, and chronic trauma exposure and PTSD are associated with increased receptor responsivity and decreased receptor expression. The research strategic priority is to replicate these findings in clinical samples not taking medication, and examine differences by age, sex, and type and length of trauma exposure.
Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.
Maus A, Figdore D, Chavan S, Ruoff C, Krahn L, et al. — 2026
OBJECTIVES: Hypocretin-1/Orexin-A is associated with stabilization of the sleep/wake cycle. Reductions of cerebrospinal fluid (CSF) concentrations of orexin-A, as determined by radioimmunoassay (RIA), are considered consistent with the diagnosis of narcolepsy type 1 (NT1). However, measuring full-length orexin-A by other methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) has proven technically challenging. In this investigation, abundant fragments of orexin-A in CSF were identified and quantified using LC-MS, which allowed assessment of the concordance with clinical RIA measurements. METHODS: Orexin-A-related peptides were immunopurified using the antibody employed in the RIA from 80 residual CSF samples submitted to our reference laboratory for RIA testing (n = 31, ≤110 pg/mL (low); n = 15, 111-200 pg/mL (intermediate); n = 34, >200 pg/mL (normal)). Enriched peptides then underwent LC-MS/MS analysis, resulting in identification of abundant orexin-A fragments. Following the identification of fragments, quantitative targeted LC-MS measurements were compared to a clinically relevant RIA assay. RESULTS: Full-length orexin-A was not detected in CSF, but two relatively abundant N-terminal orexin-A fragments, comprising amino acids 1-14 and 1-16, were identified by LC-MS/MS. Comparison with RIA yielded Spearman's correlation coefficients (ρ) of 0.91 and 0.94 for the 1-14 and 1-16 fragments, respectively. Additionally, the LC-MS and RIA method were 88% concordant for orexin-A deficient categorizations characteristic of NT1. CONCLUSIONS: Quantitative measurement of the identified orexin-A peptide fragments via LC-MS may represent a significant advance in diagnostic capabilities for evaluating central hypersomnolence disorders. These findings also lay the foundation for future studies on the diagnostic utility and clinical relevance of these orexin-A fragments.
Tackling the Orexin Conundrum: An Optimized LC-MS/MS Method Demonstrates Accurate CSF Quantification and Absence in Peripheral Blood.
Cao Y, Zhang Y, Han J, Xu Z, Zhang H, et al. — 2026
Cerebrospinal fluid (CSF) orexin-A is the gold-standard biomarker for narcolepsy type 1 (NT1), however, conventional radioimmunoassays (RIA) often suffer from cross-reactivity and overestimation, fueling long-standing conundrum regarding orexin detection in peripheral blood. In this study, we developed an ultrasensitive LC-MS/MS method (LLOQ = 0.1 pg/mL) incorporating a streamlined one-step protein precipitation protocol coupled with acid-shielding and cocktail-protection strategies to mitigate severe nonspecific adsorption and enzymatic degradation. Verification in paired CSF and blood samples from narcolepsy patients and controls revealed that orexin-B and peripheral orexins remain consistently below the detection limit (<0.1 pg/mL), proving that previously reported ng/mL levels in blood are analytical artifacts. Our LC-MS/MS approach resolved a 50-fold quantitative overestimation by RIA and significantly improved diagnostic resolution for narcolepsy type 2 (AUC = 0.73, < 0.05) where RIA failed to achieve statistical significance ( = 0.297). This study establishes a high-specificity analytical framework as a practical reference standard for refined sleep disorder diagnostics and confirms that CSF orexin-A remains the currently the most reliable clinical biomarker.